PT4004002T - Compostos macrocíclicos como agonistas de sting e seus métodos e usos - Google Patents
Compostos macrocíclicos como agonistas de sting e seus métodos e usosInfo
- Publication number
- PT4004002T PT4004002T PT207680901T PT20768090T PT4004002T PT 4004002 T PT4004002 T PT 4004002T PT 207680901 T PT207680901 T PT 207680901T PT 20768090 T PT20768090 T PT 20768090T PT 4004002 T PT4004002 T PT 4004002T
- Authority
- PT
- Portugal
- Prior art keywords
- methods
- macrocyclic compounds
- sting agonists
- sting
- agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201921029556 | 2019-07-22 | ||
IN201921051086 | 2019-12-10 | ||
IN202021003961 | 2020-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT4004002T true PT4004002T (pt) | 2024-10-07 |
Family
ID=72422197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT207680901T PT4004002T (pt) | 2019-07-22 | 2020-07-22 | Compostos macrocíclicos como agonistas de sting e seus métodos e usos |
Country Status (32)
Country | Link |
---|---|
US (1) | US20220289763A1 (pt) |
EP (1) | EP4004002B1 (pt) |
JP (1) | JP7592689B2 (pt) |
KR (1) | KR20220035955A (pt) |
CN (1) | CN114174303B (pt) |
AU (1) | AU2020319058A1 (pt) |
BR (1) | BR112022001125A2 (pt) |
CA (1) | CA3147397A1 (pt) |
CL (1) | CL2022000145A1 (pt) |
CO (1) | CO2022001814A2 (pt) |
CR (1) | CR20220029A (pt) |
DK (1) | DK4004002T3 (pt) |
EC (1) | ECSP22005485A (pt) |
ES (1) | ES2989915T3 (pt) |
FI (1) | FI4004002T3 (pt) |
GE (1) | GEP20247627B (pt) |
HR (1) | HRP20241222T1 (pt) |
HU (1) | HUE068456T2 (pt) |
IL (1) | IL289740A (pt) |
LT (1) | LT4004002T (pt) |
MA (1) | MA56674B1 (pt) |
MX (1) | MX2022000939A (pt) |
PE (1) | PE20220937A1 (pt) |
PH (1) | PH12022550175A1 (pt) |
PL (1) | PL4004002T3 (pt) |
PT (1) | PT4004002T (pt) |
RS (1) | RS66126B1 (pt) |
SA (1) | SA522431429B1 (pt) |
SI (1) | SI4004002T1 (pt) |
SM (1) | SMT202400399T1 (pt) |
WO (1) | WO2021014365A1 (pt) |
ZA (1) | ZA202201375B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114585623A (zh) | 2019-08-02 | 2022-06-03 | 梅尔莎纳医疗公司 | 双[N-((5-氨基甲酰基)-1H-苯并[d]咪唑-2-基)吡唑-5-甲酰胺]衍生物和相关化合物作为STING(干扰素基因刺激物)激动剂用于治疗癌症 |
MX2022012304A (es) | 2020-04-02 | 2022-11-30 | Mersana Therapeutics Inc | Conjugados de anticuerpo-farmaco que comprenden agonistas de sting. |
US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
US20240116909A1 (en) * | 2021-01-12 | 2024-04-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel compounds useful as sting agonists and uses thereof |
CA3207893A1 (en) * | 2021-01-15 | 2022-07-21 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
WO2024130341A1 (en) * | 2022-12-22 | 2024-06-27 | Aculeus Therapeutics Pty Ltd | Benzimidazole derivatives for the modulation of sting |
WO2025012057A1 (en) * | 2023-07-07 | 2025-01-16 | F. Hoffmann-La Roche Ag | Macrocycles for the treatment of autoimmune disease |
WO2025017045A1 (en) * | 2023-07-19 | 2025-01-23 | F. Hoffmann-La Roche Ag | Macrocycles for the treatment of autoimmune disease |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20010395A1 (it) | 2001-02-27 | 2002-08-27 | Dompe Spa | Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate |
AR046959A1 (es) | 2003-12-18 | 2006-01-04 | Tibotec Pharm Ltd | Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio |
US7488736B2 (en) | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
MY162174A (en) | 2005-10-07 | 2017-05-31 | Exelixis Inc | Azetidines mek inhibitors for the treatment of proliferative diseases |
RU2008152195A (ru) | 2006-06-15 | 2010-07-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | 2-анилино-4-(гетероциклил)аминопиримидины, как ингибиторы протеинкиназы с-альфа |
WO2008090570A1 (en) | 2007-01-25 | 2008-07-31 | Panacea Biotec Ltd | Novel antimicrobials |
TW201000447A (en) | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
WO2011091446A1 (en) * | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
WO2012083053A2 (en) * | 2010-12-15 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
AU2013366974B2 (en) | 2012-12-28 | 2017-11-02 | Nippon Zoki Pharmaceutical Co., Ltd. | Cinnamic acid amide derivative |
ES2692226T3 (es) * | 2014-06-04 | 2018-11-30 | Glaxosmithkline Intellectual Property Development Limited | Dinucleótidos cíclicos como moduladores de STING |
US20180147187A1 (en) | 2015-01-12 | 2018-05-31 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
US10844051B2 (en) | 2015-07-22 | 2020-11-24 | The Royal Institution For The Advancement Of Learning/Mcgill University | Substituted oxazoles for the treatment of cancer |
HRP20220936T1 (hr) | 2016-04-07 | 2022-10-28 | Glaxosmithkline Intellectual Property Development Limited | Heterociklički amidi korisni kao modulatori proteina |
CA3019628A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
US11352353B2 (en) | 2016-05-27 | 2022-06-07 | Hangzhou Innogate Pharma Co., Ltd. | Heterocyclic compound serving as FGFR4 inhibitor |
EA036435B1 (ru) * | 2017-02-22 | 2020-11-10 | Глэксосмитклайн Интеллекчуал Проперти Девелопмент Лимитед | Гетероциклические амиды, пригодные в качестве модуляторов белков |
WO2018234808A1 (en) | 2017-06-22 | 2018-12-27 | Curadev Pharma Limited | Small molecule modulators of human sting |
EP3642184A1 (en) | 2017-06-22 | 2020-04-29 | Curadev Pharma Limited | Small molecule modulators of human sting |
US20200172483A1 (en) | 2017-06-22 | 2020-06-04 | Curadev Pharma Limited | Heterocyclic small molecule modulators of human sting |
WO2019023635A1 (en) | 2017-07-27 | 2019-01-31 | Stingray Therapeutics, Inc. | SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER |
AU2018311966A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Benzo[b]thiophene sting agonists for cancer treatment |
EP3661499A4 (en) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme Corp. | COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO AGONISTS [B |
JP7291130B2 (ja) | 2017-10-05 | 2023-06-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | インターフェロン遺伝子の刺激物質(sting)の調節物質 |
EP3692033A1 (en) * | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
PE20220169A1 (es) | 2019-03-28 | 2022-01-28 | Lupin Ltd | Compuestos macrociclicos como agonistas de sting |
-
2020
- 2020-07-22 PT PT207680901T patent/PT4004002T/pt unknown
- 2020-07-22 ES ES20768090T patent/ES2989915T3/es active Active
- 2020-07-22 PE PE2022000120A patent/PE20220937A1/es unknown
- 2020-07-22 LT LTEPPCT/IB2020/056875T patent/LT4004002T/lt unknown
- 2020-07-22 RS RS20241052A patent/RS66126B1/sr unknown
- 2020-07-22 HU HUE20768090A patent/HUE068456T2/hu unknown
- 2020-07-22 FI FIEP20768090.1T patent/FI4004002T3/fi active
- 2020-07-22 GE GEAP202015883A patent/GEP20247627B/en unknown
- 2020-07-22 BR BR112022001125A patent/BR112022001125A2/pt unknown
- 2020-07-22 PH PH1/2022/550175A patent/PH12022550175A1/en unknown
- 2020-07-22 CR CR20220029A patent/CR20220029A/es unknown
- 2020-07-22 SI SI202030501T patent/SI4004002T1/sl unknown
- 2020-07-22 US US17/628,619 patent/US20220289763A1/en active Pending
- 2020-07-22 KR KR1020227005943A patent/KR20220035955A/ko active Pending
- 2020-07-22 CA CA3147397A patent/CA3147397A1/en active Pending
- 2020-07-22 JP JP2022504707A patent/JP7592689B2/ja active Active
- 2020-07-22 SM SM20240399T patent/SMT202400399T1/it unknown
- 2020-07-22 MX MX2022000939A patent/MX2022000939A/es unknown
- 2020-07-22 WO PCT/IB2020/056875 patent/WO2021014365A1/en active Application Filing
- 2020-07-22 PL PL20768090.1T patent/PL4004002T3/pl unknown
- 2020-07-22 MA MA56674A patent/MA56674B1/fr unknown
- 2020-07-22 CN CN202080053237.XA patent/CN114174303B/zh active Active
- 2020-07-22 HR HRP20241222TT patent/HRP20241222T1/hr unknown
- 2020-07-22 EP EP20768090.1A patent/EP4004002B1/en active Active
- 2020-07-22 AU AU2020319058A patent/AU2020319058A1/en active Pending
- 2020-07-22 DK DK20768090.1T patent/DK4004002T3/da active
-
2022
- 2022-01-10 IL IL289740A patent/IL289740A/en unknown
- 2022-01-19 SA SA522431429A patent/SA522431429B1/ar unknown
- 2022-01-21 CL CL2022000145A patent/CL2022000145A1/es unknown
- 2022-01-21 EC ECSENADI20225485A patent/ECSP22005485A/es unknown
- 2022-01-28 ZA ZA2022/01375A patent/ZA202201375B/en unknown
- 2022-02-21 CO CONC2022/0001814A patent/CO2022001814A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202201375B (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
IL294423A (en) | Compounds and methods for targeted reduction of rapidly accelerated polypeptide fibrosarcoma | |
IL288104A (en) | Heterocyclic compounds, preparation methods and their use | |
SMT202400343T1 (it) | Composti macrociclici e loro usi | |
EP3774765A4 (en) | Aza-benzothiophene compounds as sting agonists | |
ZA201906131B (en) | Herbicidal mixture, composition and method | |
EP3727401A4 (en) | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | |
IL286526A (en) | Macrocyclic compounds as sting agonists | |
IL269788B (en) | A macrocyclic compound and its uses | |
GB201617572D0 (en) | Use, method, kit, composition and antibodies | |
HUE057212T2 (hu) | Mikroorganizmusok mintavételezési eljárása, eszköz a mikroorganizmusok mintavételezéséhez és az említett eszközt tartalmazó készlet | |
EP3873484C0 (en) | NEW STING AGONISTS | |
GB201619705D0 (en) | Sliding component, material and method | |
GB201705124D0 (en) | Composition, method and use | |
GB201805089D0 (en) | Composition, method and use | |
GB201805016D0 (en) | Composition, method and use | |
SG11202105125XA (en) | Macrocyclic compound and use thereof | |
SG10201603101YA (en) | Lubricant composition, and preparation method and use thereof | |
PL3448555T3 (pl) | Stała kompozycja oczyszczająca, sposób jej otrzymywania i jej zastosowania | |
EP3362526A4 (en) | FLUORCHEMICAL COMPOSITIONS AND METHOD | |
GB201810121D0 (en) | Macrocyclic compounds and uses thereof | |
GB201716557D0 (en) | Composition, methods and uses | |
GB201610992D0 (en) | Method, composition and sensor | |
AU2015900844A0 (en) | The Game and Method |